AmpliMed anticancer drug given expanded orphan status
5th Sep 2005, 13:33 GMT
AmpliMed's lead anticancer drug Amplimexon has been granted orphan drug designation by the FDA in its indication to treat ovarian cancer.
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol